Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

  1. Pennod › Ymchwil › Adolygwyd gan gymheiriaid
  2. Cyhoeddwyd

    Review of resource-use measures in UK economic evaluations

    Ridyard, C. & Hughes, D., 2015, PSSRU Unit Costs of Health and Social Care 2015 . Curtis, L. & Burns, A. (gol.). University of Kent, Canterbury, t. 22-31 10 t.

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion CynhadleddPennodadolygiad gan gymheiriaid

  3. Cyfraniad i Gynhadledd › Ymchwil › Heb ei adolygu gan gymheiriaid
  4. Cyhoeddwyd

    Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis

    Pijeira Perez, Y. & Hughes, D., 7 Ion 2025, OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.: Abstracts from the HTAi 2024 Meeting in Seville, Spain . Special Issue S1 gol. International Journal of Technology Assessment in Health Care., Cyfrol 40.

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion CynhadleddCyfraniad i Gynhadledd

  5. Papur › Ymchwil › Heb ei adolygu gan gymheiriaid
  6. Cyhoeddwyd

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  7. Cyhoeddwyd

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  8. Cyhoeddwyd

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  9. Cyhoeddwyd

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Ion 2009, t. TP40.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  10. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  11. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  12. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Meh 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  13. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Mai 2003.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  14. Cyhoeddwyd

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  15. Cyhoeddwyd

    Adherence with HAART: pharmacoeconomic considerations

    Hughes, D. & Hughes, D. A., 1 Meh 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  16. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Gorff 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  17. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  18. Cyhoeddwyd

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Ebr 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  19. Cyhoeddwyd
  20. Cyhoeddwyd
  21. Cyhoeddwyd

    Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.

    Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  22. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  23. Cyhoeddwyd

    Biological agents for the management of Crohn's disease in adults: a systematic review, meta-analysis and multiple treatment comparison

    Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  24. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  25. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  26. Cyhoeddwyd

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Medi 2006.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  27. Cyhoeddwyd

    Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR?

    Hughes, D., Nichol, M., Manias, E., Hughes, D. A. & Schabert, V. F., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  28. Cyhoeddwyd

    Cost of non-compliance and non-persistence with medications for diabetes mellitus

    Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur